PFIZER's NORVASC, ZITHROMAX ADD MORE THAN $100 MIL. EACH IN 1st QUARTER; ZOLOFT TOPS U.S. LINE AT $334 MIL.; WORLDWIDE SALES REACH $2.26 BIL. BEFORE LIPITOR AND ARICEPT
A $94 mil. jump in Zithromax sales during the first quarter in the U.S. made the antibiotic the fastest percentage growing product in Pfizer's domestic line and the single largest new dollar contributor. Pfizer's U.S. pharmaceutical business climbed 17% to just under $1.3 bil. in the first quarter. Zithromax, at $181 mil., showed growth of 108% over $87 mil. in the first quarter last year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth